Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexlamose inhalation solution for moderate to severe COPD
2025-523020-50-00Phase 2Completed
- Sponsor
- Aer Therapeutics
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Fexlamose inhalation solution with Placebo inhalation solution (2 arms). Primary endpoint: Change from baseline in prebronchodilator FEV1 at Week 4. Started Mar 2026; status: completed.
02
Drugs
fexlamose
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-523020-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523020-50-00.